Tech Transfer eNews Blog

Antibody Patenting and Licensing Challenges in Light of Amgen v. Sanofi

By Jesse Schwartz
Published: July 25th, 2018

Over the past decade, multiple patents on therapeutic antibodies have been invalidated in the courts, often for lack of written description — and it won’t be getting any easier after the Amgen v. Sanofi Fed Circuit decision. The case indicated that even for a new class of antibodies, the written description requirement can be met only through the disclosure of a “sufficient” number of representative antibodies — including highly specific amino acid sequences. Disclosure of target antigens without the antibody disclosure will no longer cut it.

And because what constitutes a “sufficient” number is unclear, universities that don’t have the resources to characterize a large number of antibodies before applying for a patent face a significant challenge. Adding to the challenge is the retroactive application of the ruling, leaving billions in antibody patents at risk.

Research universities invest millions of dollars in discovering and developing antibodies, and they — and their potential licensees — are faced with uncertainty and heightened risk in the wake of these developments. That’s why Technology Transfer Tactics’ Distance Learning Division has tapped biotech patent expert Kevin E. Noonan, PhD, to lead this critically important webinar: Antibody Patenting and Licensing Challenges in Light of Amgen v. Sanofi, scheduled for August 23rd.

For complete program details and to register, CLICK HERE.


Posted under: Distance Learning, Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment